CSE: VGW

OTC: VGWCF

CORPORATE PRESENTATION

MARCH 2019

DISCLAIMER

This Presentation contains forward-looking statements and forward-looking information. Often, but not always, forward-looking statements can be identified by the use of words or

phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements involve known and

unknown words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words

and risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results,

performance or achievements expressed or implied by the forward-looking statements and information. Examples of such statements include: (A) the financial forecast of the

Company; (B) the intention to grow the business and operations of the Company; (C) anticipated timing for the availability of the Company’s products to market and expected sale

prices; (D) expected growth in the number of users of medical and recreational marijuana anticipated; and (E) the expansion of the Company’s business into other revenue streams.

Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this Presentation.

Such forward-looking statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to: the ability of the Company to obtain

necessary financing; the ability to complete a going public transaction; the ability to satisfy the requirements of a stock exchange; the economy generally; consumer interest in the

products of the Company; competition; and anticipated and unanticipated costs. These forward-looking statements should not be relied upon as representing the Company’s views

as of any date subsequent to the date of this Presentation. Although the Company has attempted to identify important factors that could cause actual actions, events or results to

differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended.

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such

statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements and information contained in this Presentation are

expressly qualified in their entirety by this cautionary statement. The forward-looking statements and information included in this Presentation are made as of the date of this

Presentation and the Company assumes no obligation to update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by

applicable securities legislation.

NOTICE TO RECIPIENT

This investment is suitable only for sophisticated investors for whom an investment does not constitute a complete investment program, who do not require immediate liquidity for

their investment and who fully understand and are willing to assume the risks involved. An investment may be considered to involve a substantial degree of risk, and an investor

could lose all or a substantial amount of his or her investment. This document is not an offer to sell (or solicitation of an offer to buy) any interest in the Company. These materials

may not be used or relied upon for any purpose other than as specifically contemplated by a written agreement. The materials may not be circulated outside of the recipient’s

organization, publicly referred to, or disclosed, in whole or in part, without express written permission. This presentation does not purport to be all inclusive or contain all the

information that a prospective investor may require to fully evaluate an investment in the contemplated transaction. Prospective investors should conduct their own thorough

investigation and due diligence before making an investment.

2

CSE:VGW, OTC:VGWCF

3

Our mission is to become the

world’s most trusted partner for

best-in-class cannabis

extraction, testing, formulations

and product development.

CSE:VGW, OTC:VGWCF

Largest extraction

company in Canada.

Most diverse

extraction capabilities.

In-house testing

laboratory.

High

margins.

High cashflow

visibility.

First mover

advantage.

Providing customers with the widest variety of

extraction techniques which allows them to

produce the largest range of end products.

Customized

product development.Valens formulation and testing expertise allows for

the production of a wide array of tinctures, capsules,

concentrates, vapes, topicals, beverages and edibles.

Proprietary technology

and processes.

At 240,000kg of capacity and growing, Valens

is equipped to service Canadian demand as well

as the global markets with efficiency at scale.

Setting global standards, Valens Labs was the first

ISO 17025 accredited lab for cannabis analyses and

is endorsed by $100B+ Thermo Fisher Scientific as

the Centre of Excellence in Plant Based Science.

Operating in the highest margin sub-sector of

the cannabis industry with low variability in

costs.

Substantial, reoccurring agreements with leading

producers, including Canopy, Tilray and Organigram

providing a clear revenue and cashflow path.

Incorporated in 2012, Valens was granted the first

Dealer’s License to process cannabis. Our R&D and

testing process allows us to quickly identify market

trends and adapt to a changing landscape.

4

Decades of experience have resulted in a best in class

proprietary extraction process that is optimized to

produce consistently high quality products.

CSE:VGW, OTC:VGWCF

INVESTMENT HIGHLIGHTS

2016

“The future of cannabis in Canada is coming, and we are at the forefront.”

– Tyler Robson, CEO

FUTURE*2018

5

FLOWER BASED PRODUCTSOIL BASED PRODUCTS

Source: Cowen Equity Research Report

*Valens forward-looking prediction in the short-term based on market research

29%

71%

47%53%

25%

75%

CSE:VGW, OTC:VGWCF

US MARKET SHARE ROAD MAP

OUR BELIEFSTHE MARKET IS RAPIDLY MOVING TO OIL BASED PRODUCTS

6

1

2

3

4

EXTRACTION

TESTING

FORMULATION

PRODUCT DEVELOPMENT

CSE:VGW, OTC:VGWCF

WHAT WE DOVALENS KEY FOCUS AREAS

7

1

OIL EXTRACTION

OIL WINTERIZATION

DRIED

CANNABISOIL REFINEMENT

(DISTILLATE/ISOLATE)CBD

THC

CBGCBN

WAXES

LIPIDS

FATS

CSE:VGW, OTC:VGWCF

EXTRACTIONWHAT IS IT?

Valens is the only company providing a wider variety of extraction methods

allowing us to create more end products and ultimately meeting a larger number of customer needs.

EXTRACTION

8

Capsules

Tinctures

Vapes

Topicals

Beverages

Edibles

Others

Concentrates

Vapes

Shatter/Wax

Full Spectrum

Rosin

Hash

Live Resin

Add back for

experience, flavour

and smell

1

Capsules

Tinctures

Vapes

Edibles

Super/Sub

Critical CO2 Ethanol Hydrocarbon Solvent-less Terpene

CSE:VGW, OTC:VGWCF

EXTRACTIONWHAT IS OUR COMPETITIVE ADVANTAGE?

RESIN REFINED OIL

Processing from

flower to crude oil

Processing from crude oil

to various refined stages

Formulation and product

development of oil for market

Fee for service Fee for service Fee for service

or

Revenue share

9

INCREASING MARGINS

WHITE LABEL

1

CSE:VGW, OTC:VGWCF

EXTRACTIONHOW WE GENERATE HIGH MARGINS

EXTRACTION

• Trusted by industry-leading producers

• 2 to 4 year renewable contracts with minimum

annual quantities

• Recognized for our expertise and ability to deliver

high quality extracts

EXTRACTION PARTNERSEXTRACTING FOR $45B WORTH OF MARKET CAP

A key element of [our] success is

partnerships with companies like Valens

who can offer the capacity, quality and

expertise to help ensure we deliver on our

ongoing commitment to meeting the

increasing demand of the global medical

and adult recreational cannabis markets.

-Greg Engel, CEO of Organigram

10

STRATEGIC PARTNERSGLOBAL INITIATIVES

1

…AND MORE

CSE:VGW, OTC:VGWCF

EXTRACTIONA TRUSTED INDUSTRY PARTNER

METALS PESTICIDES TERPENES RESIDUAL SOLVENTS MICROBIALS CANNABINOID PROFILES

11

First ISO 17025 accredited lab - the global gold

standard for testing laboratories.

Utilizing the latest state of the art instrumentation,

Valens can perform analyses that typically take a

minimum of 5 days in as little as 24 hours.

Working with Thermo Fisher Scientific to publish fully

validated, standardized, and turnkey solutions for

the cannabis industry to increase the confidence in

laboratory results world-wide.

Additional revenue source through third-party lab

testing (required by Health Canada for all producers)

TESTINGVALENS LABS: SETTING STANDARDS DOMESTICALLY

AND GLOBALLY FOR CANNABIS TESTING

Named a “Center of Excellence in

Plant Based Science” by Thermo

Fisher Scientific.

Annual Revenue: $24B USD

Market Cap: $104B USD

Global Employees: 70,000

2

Consumer products are built on trust. This starts and ends with reliability and consistency.

CSE:VGW, OTC:VGWCF

12

3

As the cannabis market matures, custom

formulations will drive consumer

preference more and more.

Tasteless, colorless and odorless

Full spectrum preservation or flower

emulating characteristics

Customized flavor introductions

500+ BIOACTIVE COMPOUNDS

ARE PRESENT IN CANNABIS

140+

CANNABINOIDS100+

TERPENES

20+ FLAVONOIDSPHENOLIC

AMIDES

STEROLS

CSE:VGW, OTC:VGWCF

FORMULATIONSDIFFERENT COMBINATIONS OF MOLECULES CREATE DIFFERENT CONSUMER EXPERIENCES

Alpha Pinene3%

PINEAPPLE

EXPRESS*

13

3

100+ TERPENE FORMULATIONS

Cannabinoids bind to the body’s

receptors to produce different

effects, which are further

influenced by terpenes and the

full suite of secondary compounds.

Valens has the capabilities and

expertise to create and customize

terpene formulations responsible

for consumer experience.

*Example of the terpene make-up of the

cannabis strain, Pineapple Express

CSE:VGW, OTC:VGWCF

FORMULATIONSTHE IMPORTANCE OF SECONDARY COMPOUNDS

• Shelf stable for over 360 days (not proven anywhere else)

• Zero cannabis taste, color or odor

• Provides effective, consistent dosing

• Lower dosage sufficient due to increase in bioavailability when consumed

• Faster onset making it the safer and more trusted option. Observed in 5-15 minutes versus normal 30 minutes – 2 hours.

• Faster offset making it feel exactly like an alcoholic beverage. Observed in 45 minutes – 2 hours versus normal 4 – 8 hours.

• Proprietary formula, exclusive Canadian rights

14

3

CSE:VGW, OTC:VGWCF

WATER SOLUBILITY

ONSET

OFFSET

SMELL/TASTE

CONSISTENCY

SHELF STABILITY

CURRENT PROBLEMS VALENS’ SOLUTION

FORMULATIONSSORSE EMULSION TECHNOLOGY

CANNABIS AS AN

INGREDIENT

VAPE

BEVERAGES/EDIBLES

TOPICALS/CAPSULES

TINCTURES

154

V A L E N S W H I T E L A B E L P R O D U C T O F F E R I N G S

CSE:VGW, OTC:VGWCF

PRODUCT DEVELOPMENTTHE FUTURE OF CANNABIS CONSUMPTION

GEOGRAPHIC EXPANSION

EXPORT GLOBALLY

LAUNCH BEVERAGES

& EDIBLES

LAUNCH VAPE LINE

16

KELOWNA EXPANSION

EU GMP CERTIFICATION

ORGANIC CERTIFICATION

VARIOUS MULTI-YEAR

EXTRACTION AND PRODUCT

DEVELOPMENT CONTRACTS

ACHIEVEMENTS IN 2018

EXTRACTION CAPACITY EXPANSION

8 PUBLIC MULTI-YEAR EXTRACTION AGREEMENTS

PARTNERSHIP WITH THERMO FISHER SCIENTIFIC

ISO 17025 VALENS LABS ACCREDITATION

STANDARD PROCESSING, CULTIVATION AND

ANALYTICAL TESTING LICENSES

GLOBAL PARTNERSHIPS FOR SUPPLY

GLOBAL PARTNERSHIPS FOR DISTRIBUTION

SORSE EXCLUSIVE TECH & BEVERAGE RIGHTS

OTC LISTING

KEY MANAGEMENT, ADVISORY AND BOARD

ADDITIONS

RAISED $41 MILLION IN CAPITAL

CSE:VGW, OTC:VGWCF

2018 ACHIEVEMENTS

CORPORATEWHAT WE’VE ACCOMPLISHED AND WHERE WE’RE GOING

FOCUS FOR 2019

C A N A D A

CURRENT GLOBAL PARTNERSHIPS

INCLUDE ETICANN (COLOMBIA)

AND MEDIGROWTH (AUSTRALIA)

TARGETTING EUROPEAN

DISTRIBUTION AND EXPANSION

G L O B A L

M A R K E T

17

A U S T R A L IA

C O L O M B IA

* E IG H T C A P IT A L R E S E A R C H 2 0 18

33 COUNTRIES WITH

ACTIVE MEDICAL

LEGISLATION*

CSE:VGW, OTC:VGWCF

CORPORATEGLOBAL MEDICAL MARKET ALONE ESTIMATED AT $180B ANNUALLY IN 10-20 YEARS*

Broker Date Rating Target (C$) Commentary

AltaCorp Capital Inc. Mar 14, 2019 Outperform $7.00

"Within the cannabis sector and amongst all companies we have seen, we forecast that Valens will generate one of the most attractive EBITDA margin profiles. In addition, the Company’s business model requires relatively low capital investment in comparison to the business models of most vertically integrated cannabis producers, allowing them to generate meaningful free cash flows as early as F2020. Based on our forecasted financial performance, Valens offers a very attractive opportunity to invest in what we believe is an undervalued and uniquely positioned business."

Haywood Securities Inc. Feb 7, 2019 Buy $5.25

"We believe that Valens’ proprietary extraction process and development of oil derivative based products, both white-label and its own branded products should result in strong revenue growth and solid EBITDA margins. Throughout 2019 we expect the Company to scale revenues through its existing agreements while also announcing further agreements to leverage its processing capacity."

Mackie Research Capital Corp.

Feb 27, 2019 Buy $6.00

Over the past couple of months, Valens has signed multi-year cannabis extraction agreements with Tilray, Organigram, Canopy Growth, Sundial Growers, Harvest One and GTEC Holdings. Following the contract announcements with Tilray and Organigram, we have made adjustments to our revenueand earnings forecasts through F2020 and on the back of these new forecasts we are increasing our target price to $6.00 from $4.50.

ANALYSTS OUTLOOK

CAPITALIZATION TABLE

18

CSE:VGW, OTC:VGWCF

CORPORATEFINANCIALS & OUTLOOK

(In CAD$MM, unless otherwise noted)Share Price: As of 21st of March 2019 $3.14

Basic Shares O/S 108.6 Fully Diluted Shares O/S 123.9

Equity Value $389.0 Cash and Cash Equivalents $60.8 Investments in Other Companies $4.7 ITM Securities $30.9 Debt $0.0

Enterprise Value $292.6

Financials (Based on Analyst Estimates) CY2019 CY2020 CY2021Revenue $48.7 $116.5 $171.2 EBITDA $23.6 $61.5 $84.4

Trading Multiples CY2019 CY2020 CY2021EV/Revenue 6.0x 2.5x 1.7xEV/EBITDA 12.4x 4.8x 3.5x

Source: Company Filings, S&P Capital IQ, AltaCorp Capital Inc.

As of March 21st, 2019; Shares outstanding based on most recent quarterly financials and adjusted for share issuance

transactions and other significant publicly disclosed transactions; presented as Treasury Stock Method

NO. OF ANNOUNCED TOLL

PROCESSING AGREEMENTS

WITH LICENSED PRODUCERS

NO. OF ANNOUNCED TOLL

AGREEMENTS IN TOP 10*

CURRENT ANNUAL

EXTRACTION CAPACITY

TYPES OF EXTRACTION

ISO 17025 ACCREDITED

TESTING LAB

EU GMP CERTIFICATION

ORGANIC CERTIFICATION

MARKET CAP (CAD$) Per Comp Table (p.25)

8

4

240,000KG

5

Y

PENDING

PENDING

389M

1

1

30,000KG

2

N

N

N

365M

5

1

150,000KG

1

N

PENDING

N

456M

2

1

56,000KG

1

N

N

N

323M

*Companies ranked per market cap

Sourced from company presentations and news releases

19

CSE:VGW, OTC:VGWCF

COMPETITIVE LANDSCAPE

Largest extraction

company in Canada.

Most diverse

extraction capabilities.

In-house testing

laboratory.

High

margins.

High cashflow

visibility.

First mover

advantage.

Providing customers with the widest variety of

extraction techniques which allows them to

produce the largest range of end products.

Customized

product development.Valens formulation and testing expertise allows for

the production of a wide array of tinctures, capsules,

concentrates, vapes, topicals, beverages and edibles.

Proprietary technology

and processes.

At 240,000kg of capacity, Valens is equipped to

service Canadian demand as well as the global

markets with efficiency at scale.

Setting global standards, Valens labs was the first

ISO 17025 accredited lab for cannabis analyses and

is endorsed by $100B+ Thermo Fisher Scientific as

the Centre of Excellence in Plant Based Science.

Operating in the highest margin sub-sector of

the cannabis industry with low variability in

costs.

Substantial, reoccurring agreements with leading

producers, including Canopy, Tilray and Organigram

providing a clear revenue and cashflow path.

Incorporated in 2012, Valens was granted the first

Dealer’s License to process cannabis. Our R&D and

testing process allows us to quickly identify market

trends and adapt to a changing landscape.

20

Decades of experience have resulted in a best in class

proprietary extraction process that is optimized to

produce consistently high quality products.

CSE:VGW, OTC:VGWCF

INVESTMENT HIGHLIGHTS

21

W W W . V A L E N S G R O W O R K S . C O M

L O C A T I O N

2 3 0 C A R I O N R D .

K E L O W N A , B R I T I S H C O L U M B I A

C O N T A C T U S

S C O T T @ V A L E N S G R O W O R K S . C O M

( 7 0 5 ) 8 8 8 - 2 7 5 6

22

CSE:VGW, OTC:VGWCF

Share Market Equity Total Enterprise Revenue(1) EBITDA(1) EV/Revenue EV/EBITDA

Ticker Price Cap(1) Value Debt Value CY2019E CY2020E CY2019E CY2020E CY2019E CY2020E CY2019E CY2020E

(C$) (C$ MM) (C$MM) (C$MM) (C$MM) (C$MM) (C$MM) (C$MM) (C$MM) (x) (x) (x) (x)Canadian Large Cap CompaniesCanopy Growth Corporation TSX:WEED $61.50 $29,920 $29,920 $61 $19,242 $686 $1,224 $92 $296 28.0x 15.7x 209.9x 65.0xAurora Cannabis Inc. TSX:ACB $12.78 $14,448 $14,448 $829 $14,039 $586 $1,129 $36 $302 23.9x 12.4x 390.7x 46.4xTilray, Inc. NasdaqGS:TLRY $94.09 $9,575 $9,575 $642 $9,353 $282 $594 ($47) $58 33.2x 15.7x >500.0x >100.0xCronos Group Inc. TSX:CRON $27.47 $11,961 $11,961 $71 $8,104 $110 $259 $38 $90 74.0x 31.3x 215.6x 89.9xAphria Inc. TSX:APHA $13.39 $3,450 $3,450 $55 $3,247 $570 $973 $87 $228 5.7x 3.3x 37.3x 14.2xHEXO Corp. TSX:HEXO $9.04 $2,671 $2,671 $51 $2,141 $185 $453 $24 $122 11.6x 4.7x 88.1x 17.6xOrganiGram Holdings Inc. TSXV:OGI $9.39 $1,542 $1,542 $13 $1,407 $157 $256 $60 $99 8.9x 5.5x 23.4x 14.3xCannTrust Holdings Inc. TSX:TRST $13.31 $1,581 $1,581 $10 $1,393 $181 $281 $50 $93 7.7x 5.0x 27.8x 14.9xThe Green Organic Dutchman TSX:TGOD $5.02 $1,619 $1,619 $0 $1,158 $93 $510 ($8) $102 12.4x 2.3x NMF 11.4xThe Supreme Cannabis Company, Inc. TSX:FIRE $2.25 $841 $841 $105 $750 $96 $163 $26 $47 7.8x 4.6x 28.8x 15.9xZenabis Global Inc. TSXV:ZENA $3.29 $709 $709 $75 $665 $167 $337 $13 $80 4.0x 2.0x 51.6x 8.3xThe Flowr Corporation TSXV:FLWR $6.00 $597 $597 $0 $539 $24 $94 ($0) $29 22.7x 5.7x NMF 18.6xAleafia Health Inc. TSX:ALEF $2.18 $622 $622 $20 $539 $142 $300 $25 $84 3.8x 1.8x 21.6x 6.4xEmerald Health Therapeutics, Inc. TSXV:EMH $4.45 $725 $725 $25 $643 $4 N/A ($19) ($16) >50.0x N/A NMF NMFWestleaf Inc. TSXV:WL $2.91 $434 $434 $4 $410 N/A N/A N/A N/A N/A N/A N/A N/AVIVO Cannabis Inc. TSXV:VIVO $1.12 $338 $338 $45 $277 $75 $196 $11 $54 3.7x 1.4x 24.2x 5.1xWeedMD Inc. TSXV:WMD $2.08 $256 $256 $0 $201 $59 $140 $16 $42 3.4x 1.4x 12.3x 4.8x48North Cannabis Corp. TSXV:NRTH $1.50 $265 $265 $2 $201 N/A N/A N/A N/A N/A N/A N/A N/AWayland Group Corp. CNSX:WAYL $0.91 $176 $176 $26 $129 $124 $176 $16 $43 1.0x 0.7x 8.3x 3.0xDelta 9 Cannabis Inc. TSXV:NINE $1.75 $150 $150 $0 $111 $83 $161 $21 $29 1.3x 0.7x 5.2x 3.8xInvictus MD Strategies Corp. TSXV:GENE $0.84 $106 $106 $1 $95 $69 $84 $23 $22 1.4x 1.1x 4.2x 4.4xJames E. Wagner Cultivation Corporation TSXV:JWCA $1.04 $99 $99 $6 $89 $35 $59 $3 $16 2.6x 1.5x 35.0x 5.7xHarvest One Cannabis Inc. TSXV:HVT $1.08 $249 $249 $2 $192 $57 $126 $9 $36 3.4x 1.5x 21.7x 5.4xBeleave Inc. CNSX:BE $0.09 $39 $39 $6 $43 $36 $12 ($14) $7 1.2x 3.7x NMF 6.6xIndiva Limited TSXV:NDVA $0.54 $46 $46 $5 $34 $20 $67 ($3) $19 1.7x 0.5x NMF 1.8xMean 12.0x 5.6x 70.9x 17.3xCanadian Extraction CompaniesMediPharm Labs Corp. TSXV:LABS $3.39 $456 $456 $2 $404 $97 $184 $21 $55 4.2x 2.2x 19.1x 7.3xNeptune Wellness Solutions Inc. TSX:NEPT $4.28 $356 $356 $4 $330 $53 $119 $10 $28 6.3x 2.8x 32.1x 11.6xValens Groworks Corp. CNSX:VGW $3.14 $389 $389 $0 $292 $49 $117 $24 $61 6.0x 2.5x 12.4x 4.8xRadient Technologies Inc. TSXV:RTI $1.07 $323 $323 $7 $273 N/A N/A N/A N/A N/A N/A N/A N/AMean 5.5x 2.5x 21.2x 7.9x

Mean - All 11.2x 5.2x 63.5x 16.1x

Source: Company Filings, S&P Capital IQ, AltaCorp Capital

As of March 21st, 2019; shares outstanding based on most recent quarterly financials and adjusted for share issuance transactions and other significant publicly disclosedtransactions; presented as fully diluted with all in-the-money securities added to the equity value and cash proceeds added to diluted cash balance; N/D = Not Disclosed (1) Basedon Analyst consensus estimates

APPENDIX: COMP TABLE

23

Scott Young

Head of Investor Relations

Mr. Young has spent the past 15 years working in the

capital market sectors of Canada, the United States and

Europe. Beyond this, he has extensive business

development experience in Hong Kong, North and South

America.

Dawn Visintainer, M.Sc.

Head of Quality Assurance

Mrs. Visintainer has extensive experience in QA/QC

laboratories as well as being a research scientist in the

natural health products industry. She also has experience

setting up and managing ISO 17025 accredited labs in both

the natural health space and the cannabis space.

Everett Knight

Executive Vice President, Strategy & Investments

Mr. Knight holds almost a decade of experience in Portfolio

Management and Investments. At Matco Financial, he

launched the first ever institutional long only cannabis fund in

Canada and managed a small cap fund, ranked #1 in its

category.

Chris Buysen, MPAcc CPA, CA

Chief Financial officer

Mr. Buysen has over 15 years of diverse financial

experience working as a senior financial executive with

many public and private organizations in a wide range of

industries.

Anderson Smith

Head of Regulatory Affairs

Anderson was been involved in the scientific analytical

testing space specializing in the analysis of natural health

products for over 15 years. He brings this expertise coupled

with his extensive knowledge of regulatory regime to

Valens.

Chantel Popoff

Chief Operating Officer

Ms. Popoff has over a decade of experience in managing

21+ Western Canadian retail pharmacy chains, including

Shoppers Drug Mart. She also has over 6 years of senior

managerial experience in the Canadian natural health

food industry.

Quinn Shiskin

Head of Production

Mr. Shiskin brings his knowledge of extraction from 12 years

of experience as a dual ticketed Red Seal tradesman.

Throughout this time he studied the cannabis industry with

top alchemists in the US creating a deep understanding of

the plant from seed to oil, specializing in all methods of

extraction.

Tyler Robson, B.Sc.

Director, Chief Executive Officer and Co-founder.

Mr. Robson has over a decade of cannabis R&D, plant

innovation and life sciences experience. He previously held

the position of COO of Valens Agritech Ltd. prior to

becoming CEO in 2017.

CSE:VGW, OTC:VGWCF

APPENDIX: KEY MANAGEMENT

Brett Channer

Advisor, CEO of Mass Minority, Past CEO of Saatchi +

Saatchi

Mr. Channer has over 25 years of marketing industry

experience. He was responsible for leading Saatchi Canada

to “Most Improved Agency in Canada” as well as one of the

Top 10 creative agencies in Canada and becoming one of

the top performing agencies for growth in the Saatchi

Network. Tyler Robson, B.Sc.

Director, CEO and Co-founder

Mr. Robson has over a decade of cannabis R&D, plant

innovation and life sciences experience. He previously held

the position of COO of Valens Agritech Ltd. “Top 100

Leaders in Health Care” by IFAH.

Ashley McGrath

Director, President & Owner of Glencoe Developments Inc.

Mr. McGrath has been involved in real estate development for

14 years, overseeing all aspects of the development business

and oversees the management of multiple development

companies in the commercial, residential and agricultural

space.

Chris Irwin

Director, Partner at Irwin Lowy LLP.

Mr. Irwin advises a number of public companies on a

variety of matters including continuous disclosure and

regulatory matters, reverse takeover transactions, initial

public offerings and take over bids.

Nitin Kaushal, CPA, CA

Director, Managing Director, Corporate Finance at PwC

Canada. Mr. Kaushal has over 30 years of finance and

investment expertise including having held a number of

senior roles with Canadian investment banks, private

equity and venture capital industry.

Chris Buysen, MPAcc CPA, CA

Director, CFO

Mr. Buysen has over 15 years of diverse financial

experience working as a senior financial executive with

many public and private organizations in a wide range

industries.

Phil Donne

Advisor, Past President/CEO of Campbell Company of

Canada, Past CEO of Kellogg Canada

Mr. Donne brings over 30 years of international brand

management, re-structures and bold brand and

communication initiatives including the re-launch of Vector

cereal which still remains the largest new cereal product in

20 years.

24

CSE:VGW, OTC:VGWCF

APPENDIX: BOARD & ADVISORS